Cargando…
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005219/ https://www.ncbi.nlm.nih.gov/pubmed/33810033 http://dx.doi.org/10.3390/jcm10061303 |
_version_ | 1783672084178665472 |
---|---|
author | Bartoli, Francesco Riboldi, Ilaria Bachi, Bianca Calabrese, Angela Moretti, Federico Crocamo, Cristina Carrà, Giuseppe |
author_facet | Bartoli, Francesco Riboldi, Ilaria Bachi, Bianca Calabrese, Angela Moretti, Federico Crocamo, Cristina Carrà, Giuseppe |
author_sort | Bartoli, Francesco |
collection | PubMed |
description | Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders. |
format | Online Article Text |
id | pubmed-8005219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80052192021-03-29 Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review Bartoli, Francesco Riboldi, Ilaria Bachi, Bianca Calabrese, Angela Moretti, Federico Crocamo, Cristina Carrà, Giuseppe J Clin Med Review Although cannabis’ major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders. MDPI 2021-03-22 /pmc/articles/PMC8005219/ /pubmed/33810033 http://dx.doi.org/10.3390/jcm10061303 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bartoli, Francesco Riboldi, Ilaria Bachi, Bianca Calabrese, Angela Moretti, Federico Crocamo, Cristina Carrà, Giuseppe Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title_full | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title_fullStr | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title_full_unstemmed | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title_short | Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review |
title_sort | efficacy of cannabidiol for δ-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders: a narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005219/ https://www.ncbi.nlm.nih.gov/pubmed/33810033 http://dx.doi.org/10.3390/jcm10061303 |
work_keys_str_mv | AT bartolifrancesco efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT riboldiilaria efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT bachibianca efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT calabreseangela efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT morettifederico efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT crocamocristina efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview AT carragiuseppe efficacyofcannabidiolford9tetrahydrocannabinolinducedpsychoticsymptomsschizophreniaandcannabisusedisordersanarrativereview |